DNA damage response specialist Artios Ltd. has closed an oversubscribed $115 million series D after delivering positive phase I/IIa data for its two lead programs.

Cornerstone Robotics Ltd. raised an oversubscribed $200 million series D round to accelerate commercialization of its flagship product, the Sentire Endoscopic Surgical System.

Synchron Inc.'s recent $200 million raise for its Stentrode brain-computer interface platform comes at a pivotal time for the technology. Advances in BCI development, ongoing clinical trials and growing market demand are drawing increased investor interest in the technology which has the potential to transform the lives of millions of people. At the same time, government agencies are closely monitoring the field, recognizing the potential while urging caution about the risks involved.